EN
Related Links
Press Releases
Home News

Press Releases

REAL-WORLD EVIDENCE OF GLP-1RAS PUBLISHED IN AN INTERNATIONAL JOURNAL REVEALS BETTER OPTION HANSOH PHARMA’S FULAIMEI PROVIDES FOR DKD PATIENTS
Release Date：2024/08/15
Font Size

A real-world study of GLP-1 receptor agonists (GLP-1RAs) for treating patients with diabetic kidney disease (DKD) was recently published in the international journal Diabetes, Metabolic Syndrome and Obesity.



This retrospective, single-arm real-world study included a total of 364 patients with mild-to-moderate DKD who had been treated with GLP-1RAs for at least 6 months. A hundred and fifty-nine cases were administered PEG-Loxenatide (trade name: Fulaimei), 104 cases Dulaglutide, 52 cases Semaglutide, and 49 cases Liraglutide. The primary endpoint was hemoglobin A1c (HbA1c) levels after 6 months treatment[1].

 

The results of the study showed that six months of treatment with GLP-1RAs resulted in a significant decrease of 1.77% in the mean HbA1c level, a decrease of 40.3% in the urinary albumin-to-creatinine ratio (UACR), and substantial improvements in 24-hour urinary protein and estimated glomerular filtration rate (eGFR) (all p<0.001). In addition, significant improvements were discovered in patients regarding fasting blood glucose, body weight, blood pressure, and lipid profile (all p<0.001).

 

Notably, patients treated with PEG-Loxenatide accounted for the largest number in this study, but incidences of gastrointestinal adverse events (17.6% vs 30.6% to 51%) and hypoglycemia (3.1% vs 8.2% to 11.5%) were lower compared with those treated with other GLP-1RAs.

 

The study also found GLP-1RAs reduced proteinuria independently of ACEIs/ARBs, and earlier application of GLP-1RA resulted in earlier benefits[1].

 

DKD is one of the major complications of diabetes[2]. About 30-40% of diabetic patients suffer from DKD[3], which is the main cause of end-stage renal disease (ESRD)[4].

 

Previously, a randomized controlled trial demonstrated that the efficacy of PEG-Loxenatide in patients with mild-to-moderate DKD was comparable to that of the first-line SGLT2 inhibitors, such as Dapagliflozin, with an additional benefit of improved lipid levels[5]. This real-world study reaffirms that PEG-Loxenatide has demonstrated multiple benefits, including blood glucose reduction, antihypertension, weight loss, lipid improvement, and delayed renal disease progression in mild-to-moderate DKD patients, and also displayed a more favorable safety profile compared with other GLP-1RAs, all of which help to improve patients' quality of life and compliance. PEG-Loxenatide provides more benefits to patients and achieves a superior safety profile, offering a better therapeutic option to DKD patients in the future.

 

Abstract

 

Background:

Cardiovascular outcome trials indicate renal benefits of glucagon-like peptide-1 receptor agonists (GLP-1RAs); however, real-world efficacy and safety studies in Diabetic kidney disease (DKD) are scarce.

 

Methods:

This retrospective, single-arm real-world trial involved adults with DKD treated with GLP-1RA for at least 6 months. The primary endpoint was hemoglobin A1c (HbA1c) levels after 6 months.

 

Results:

This study included a total of 364 patients with DKD, 153 (42.0%) of whom were female. The median disease duration was 8.0 years, and the mean values of age, HbA1c level, body mass index, and the urinary albumin-to-creatinine ratio (UACR) were 52.1 years, 8.6%, 27.8 kg/m2, and 88.0 mg/g, respectively. Additionally, 73.6% and 26.4% of patients had mild and moderate DKD, respectively. Following 6 months of GLP-1RA treatment, the mean HbA1c level and UACR declined by 1.77% and 40.3%, respectively (both p < 0.001). Compared to their baseline values, patients exhibited significant improvements in 24-h urinary protein, estimated glomerular filtration rate (eGFR), fasting blood glucose, body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (all p < 0.001). Patients with a disease duration of <10 years had more pronounced changes in the HbA1c level, UACR, and eGFR (all p < 0.001) than those with a disease duration of ≥10 years. Changes in SBP and DBP were more pronounced in patients also taking angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEis/ARBs) than in those not taking ACEis/ARBs, whereas the changes in UACR and eGFR did not significantly differ.

 

Conclusion:

Six-month GLP-1RA treatment improves glucose, blood pressure, lipids, and body weight in patients with mild-to-moderate DKD while slowing down kidney disease progression. It independently reduces proteinuria beyond ACEi/ARB impact, with early use yielding faster outcomes, supporting evidence-based practice.

 

Keywords:

diabetic kidney disease, type 2 diabetes, GLP-1RA, HbA1C, UACR



About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).

Statements

1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.

Forward-Looking Statements

This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).